<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864616</url>
  </required_header>
  <id_info>
    <org_study_id>VCD-060</org_study_id>
    <nct_id>NCT01864616</nct_id>
  </id_info>
  <brief_title>The Impact of Vitamin D on Disease Activity in Crohn's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dania Alrefai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr.Jennifer Jones</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr.Hani Jawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr.Wael El-matary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saudi Arabian Cultural Bureau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Saudi Arabia: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose for this study is to determine the effect of vitamin D supplementation on
      disease activity in Crohn's disease patients in Canada and Saudi Arabia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis 1: Patients who are suffering from Crohn's disease are at risk of vitamin D
      deficiency.

      To determine vitamin D status and disease activity in Crohn's disease cases in Canada and
      Saudi Arabia.

      Hypothesis 2: Providing vitamin D in doses higher than RDA (Recommended Dietary Allowance)
      reduces disease activity in Crohn's disease cases.

      To evaluate the impact vitamin D in doses higher than RDA (Recommended Dietary Allowance) on
      disease activity in Crohn's disease patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The changes in disease activity on groups</measure>
    <time_frame>(0), 5 weeks, 9 weeks, after 2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We have 4 time points, baseline (0), Week 5, Week 9 (termination) and Week 17 (follow up) To measure the disease activity, we will examine C- reactive protein levels &quot;blood test&quot;, Fecal fat &quot; stool test&quot; and Crohn's disease activity index (CDAI)&quot;tool&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>0, 5 weeks, 9 weeks, 2 months later</time_frame>
    <safety_issue>No</safety_issue>
    <description>We have 4 time points, baseline (0), Week 5, Week 9 (termination) and Week 17 (follow up). We will use 24-hour dietary recalls for 9 different days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vitamin D status</measure>
    <time_frame>(0), Week 5, Week 9 (termination) and 2 months later</time_frame>
    <safety_issue>No</safety_issue>
    <description>We have 4 time points, baseline (0), Week 5, Week 9 (termination) and Week 17 (follow up) vitamin D status: Blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>(0), Week 5, Week 9 (termination) and 2 months later (follow up)</time_frame>
    <safety_issue>No</safety_issue>
    <description>We have 4 time points, baseline (0), Week 5, Week 9 (termination) and Week 17 (follow up). We will use Health related quality of life questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn Disease,</condition>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3, 10,000 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 2,000 IU daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 600 IU daily (Control group, RDA level)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosis with an active Crohn's disease,

          -  age above of 16 years

        Exclusion Criteria:

          -  remission or the duration of disease is more than 2 years,

          -  pregnancy,

          -  liver or kidney failure,

          -  inability to take oral supplements or medicine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassanali Vatanparast, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Saskatoon, SK,Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Jones, MD,MSc,FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Royal University Hospital, Saskatoon, Saskatchewan, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hani Jawa, MBBS,ABIM,FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>King Abdulaziz University, jeddah, Saudi Arabia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wael El-matary, MBChB,MSc,MD,FRCPCH</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dania Alrefai, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassanali Vatanparast, MD, PhD</last_name>
    <phone>306-966-6341</phone>
    <email>vatan.h@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>IBD clinic; Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Jones, MD,MSc, FRCPC</last_name>
      <phone>306-966-6341</phone>
      <email>j.jones@usask.ca</email>
    </contact>
    <contact_backup>
      <last_name>HassanAli Vatanparast, MD,PhD</last_name>
      <phone>306-966-6341</phone>
      <email>vatan.h@usask.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Hassanali Vatanparast, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hani Jawa, MBBS,ABIM,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael El-matary, MBChB,MSc,MD,FRCPCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Jones, MD,MSc,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dania A Alrefai, M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Department; King Abdulaziz University Hospital</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hani A Jawa, PHD</last_name>
      <phone>+96626401000</phone>
      <email>jawa.hani@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dania Alrefai, M.Sc</last_name>
      <phone>+13068814026</phone>
      <email>dania.alrefai@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hassanali Vatanparast, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Jones, MD,MSc,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hani Jawa, MBBS,ABIM,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wael El-matary, MBChB,MSc,MD,FRCPCH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dania Alrefai, M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <link>
    <url>http://www.usask.ca/pharmacy-nutrition/the-college/faculty-staff_contacts/nutrition_and_dietetics/vatanparast_hassanali.php</url>
    <description>investigator: Hassanali Vatanparast</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 24, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Hassanali Vatanparast</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Crohn disease</keyword>
  <keyword>Disease activity</keyword>
  <keyword>Inflammation</keyword>
  <keyword>prevention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
